This list is based on the watchlists of people on Stock Events who follow BIOV.SW. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ansamycin leads from the BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.
FAQs
What is BioVersys stock price today?▼
The current price of BIOV.SW is CHF23.20 CHF — it has decreased by -1.28% in the past 24 hours. Watch BioVersys stock price performance more closely on the chart.
What is BioVersys stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on SIX Swiss Exchange exchange BioVersys stocks are traded under the ticker BIOV.SW.
Is BioVersys stock price growing?▼
BIOV.SW stock has fallen by -5.31% compared to the previous week, the month change is a -14.07% fall, over the last year BioVersys has showed a -3.33% decrease.
When is the next BioVersys earnings date?▼
BioVersys is going to release the next earnings report on March 31, 2027.
What were BioVersys earnings last quarter?▼
BIOV.SW earnings for the last quarter are -2.66 CHF per share, whereas the estimation was -2 CHF resulting in a -33% surprise. The estimated earnings for the next quarter are N/A CHF per share.
What is BioVersys revenue for the last year?▼
BioVersys revenue for the last year amounts to 800,000 CHF.
What is BioVersys net income for the last year?▼
BIOV.SW net income for the last year is -21.83M CHF.
How many employees does BioVersys have?▼
As of November 2, 2026, the company has 38 employees.
In which sector is BioVersys located?▼
BioVersys operates in the Other sector.
When did BioVersys complete a stock split?▼
BioVersys has not had any recent stock splits.
Where is BioVersys headquartered?▼
BioVersys is headquartered in Basel, Switzerland.